Last Updated: November 16, 2026

CAMZYOS Drug Patent Profile

« Back to Dashboard


Which patents cover Camzyos, and when can generic versions of Camzyos launch?

Camzyos is a drug marketed by Bristol and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in CAMZYOS is mavacamten. One supplier is listed for this compound. Additional details are available on the mavacamten profile page.

DrugPatentWatch® Generic Entry Outlook for Camzyos

Camzyos was eligible for patent challenges on April 28, 2026.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 28, 2036. This may change due to patent challenges or generic licensing.

There have been seven patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

< Available with Subscription >

  Start Trial

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for CAMZYOS?
  • What are the global sales for CAMZYOS?
  • What is Average Wholesale Price for CAMZYOS?
Summary for CAMZYOS
Paragraph IV (Patent) Challenges for CAMZYOS
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
CAMZYOS Capsules mavacamten 2.5 mg, 5 mg, 10 mg and 15 mg 214998 7 2026-04-28

US Patents and Regulatory Information for CAMZYOS

CAMZYOS is protected by two US patents and three FDA Regulatory Exclusivities.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of CAMZYOS is ⤷  Start Trial.

This potential generic entry date is based on patent RE50050.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bristol CAMZYOS mavacamten CAPSULE;ORAL 214998-005 Sep 30, 2026 RX Yes No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Bristol CAMZYOS mavacamten CAPSULE;ORAL 214998-004 Apr 28, 2022 RX Yes No RE50050 ⤷  Start Trial Y Y ⤷  Start Trial
Bristol CAMZYOS mavacamten CAPSULE;ORAL 214998-002 Apr 28, 2022 RX Yes Yes 9,585,883 ⤷  Start Trial ⤷  Start Trial
Bristol CAMZYOS mavacamten CAPSULE;ORAL 214998-001 Apr 28, 2022 RX Yes No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Bristol CAMZYOS mavacamten CAPSULE;ORAL 214998-003 Apr 28, 2022 RX Yes No 9,585,883 ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for CAMZYOS

When does loss-of-exclusivity occur for CAMZYOS?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 14281408
Patent: Pyrimidinedione compounds against cardiac conditions
Estimated Expiration: ⤷  Start Trial

Patent: 18264088
Patent: Pyrimidinedione compounds against cardiac conditions
Estimated Expiration: ⤷  Start Trial

Patent: 20204271
Patent: Pyrimidinedione compounds against cardiac conditions
Estimated Expiration: ⤷  Start Trial

Patent: 22202298
Patent: Pyrimidinedione compounds against cardiac conditions
Estimated Expiration: ⤷  Start Trial

Patent: 24202464
Patent: Pyrimidinedione compounds against cardiac conditions
Estimated Expiration: ⤷  Start Trial

Brazil

Patent: 2015031864
Patent: compostos de pirimidinadiona contra as condições cardíacas
Estimated Expiration: ⤷  Start Trial

Canada

Patent: 15967
Patent: COMPOSES DE PYRIMIDINE-DIONE CONTRE LES AFFECTIONS CARDIAQUES (PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS)
Estimated Expiration: ⤷  Start Trial

Chile

Patent: 15003689
Patent: Compuestos derivados de 6-(bencil, heteroaril)aminopirimidina-2,4(1h,3h)-diona y sus sales; composicion farmaceutica que los comprende; y su uso para tratar una cardiomiopatia hipertrofica (hcm) o un trastorno cardiaco que tiene una caracteristica patofisiologica asociada con hcm.
Estimated Expiration: ⤷  Start Trial

China

Patent: 5473576
Patent: Pyrimidinedione compounds against cardiac conditions
Estimated Expiration: ⤷  Start Trial

Patent: 9384729
Patent: 针对心脏病症的嘧啶二酮化合物 (Pyrimidinedione compounds against cardiac conditions)
Estimated Expiration: ⤷  Start Trial

Costa Rica

Patent: 160032
Patent: COMPUESTOS DE PIRIMIDINODIONA CONTRA ESTADOS CARDÍACOS
Estimated Expiration: ⤷  Start Trial

Croatia

Patent: 0200379
Estimated Expiration: ⤷  Start Trial

Cyprus

Patent: 22964
Estimated Expiration: ⤷  Start Trial

Patent: 23027
Estimated Expiration: ⤷  Start Trial

Denmark

Patent: 10910
Estimated Expiration: ⤷  Start Trial

Dominican Republic

Patent: 015000300
Patent: COMPUESTOS DE PIRIMIDINODIONA CONTRA ESTADOS CARDÍACOS
Estimated Expiration: ⤷  Start Trial

Eurasian Patent Organization

Patent: 0846
Patent: СОЕДИНЕНИЯ ПИРИМИДИНДИОНА (PYRIMIDINEDIONE COMPOUNDS)
Estimated Expiration: ⤷  Start Trial

Patent: 1690066
Patent: СОЕДИНЕНИЯ ПИРИМИДИНДИОНА
Estimated Expiration: ⤷  Start Trial

Patent: 1891009
Patent: СОЕДИНЕНИЯ ПИРИМИДИНДИОНА
Estimated Expiration: ⤷  Start Trial

European Patent Office

Patent: 10910
Patent: COMPOSÉS PYRIMIDINEDIONE CONTRE LES MALADIES CARDIAQUES (PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS)
Estimated Expiration: ⤷  Start Trial

Patent: 02352
Patent: COMPOSÉ DE PYRIMIDINEDIONE CONTRE LES MALADIES CARDIAQUES (PYRIMIDINEDIONE COMPOUND AGAINST CARDIAC CONDITIONS)
Estimated Expiration: ⤷  Start Trial

Finland

Patent: 0230036
Estimated Expiration: ⤷  Start Trial

France

Patent: C1047
Estimated Expiration: ⤷  Start Trial

Guatemala

Patent: 1500348
Patent: COMPUESTOS DE PIRIMIDINODIONA CONTRA ESTADOS CARDÍACOS
Estimated Expiration: ⤷  Start Trial

Hong Kong

Patent: 23930
Patent: 對抗心臟疾病的嘧啶化合物 (PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS)
Estimated Expiration: ⤷  Start Trial

Hungary

Patent: 47566
Estimated Expiration: ⤷  Start Trial

Patent: 300042
Estimated Expiration: ⤷  Start Trial

Israel

Patent: 3222
Patent: תרכובת פירימידינדיאון נגד הפרעות לבביות (Pyrimidinedione compounds against cardiac conditions)
Estimated Expiration: ⤷  Start Trial

Patent: 5837
Patent: תרכובות פירימידינדיאון נגד הפרעות לבביות (Pyrimidinedione compounds against cardiac conditions)
Estimated Expiration: ⤷  Start Trial

Patent: 5971
Patent: תרכובות פירימידינדיאון נגד הפרעות לבביות (Pyrimidinedione compounds against cardiac conditions)
Estimated Expiration: ⤷  Start Trial

Patent: 2299
Patent: תרכובות פירימידינדיאון נגד הפרעות לבביות (Pyrimidinedione compounds against cardiac conditions)
Estimated Expiration: ⤷  Start Trial

Patent: 0829
Patent: תרכובות פירימידינדיאון נגד הפרעות לבביות (Pyrimidinedione compounds against cardiac conditions)
Estimated Expiration: ⤷  Start Trial

Japan

Patent: 03213
Estimated Expiration: ⤷  Start Trial

Patent: 80734
Estimated Expiration: ⤷  Start Trial

Patent: 76556
Estimated Expiration: ⤷  Start Trial

Patent: 16522263
Patent: 心臓状態に対するピリミジンジオン化合物
Estimated Expiration: ⤷  Start Trial

Patent: 20019809
Patent: 心臓状態に対するピリミジンジオン化合物 (PYRIMIDINEDIONE COMPOUNDS FOR CARDIAC CONDITIONS)
Estimated Expiration: ⤷  Start Trial

Patent: 22036966
Patent: 心臓状態に対するピリミジンジオン化合物
Estimated Expiration: ⤷  Start Trial

Patent: 24010108
Patent: 心臓状態に対するピリミジンジオン化合物 (PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS)
Estimated Expiration: ⤷  Start Trial

Lithuania

Patent: 10910
Estimated Expiration: ⤷  Start Trial

Malaysia

Patent: 0860
Patent: PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS
Estimated Expiration: ⤷  Start Trial

Mexico

Patent: 15017865
Patent: COMPUESTOS DE PIRIMIDINODIONA CONTRA ESTADOS CARDIACOS. (PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS.)
Estimated Expiration: ⤷  Start Trial

Patent: 21005326
Patent: COMPUESTOS DE PIRIMIDINODIONA CONTRA ESTADOS CARDIACOS. (PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS.)
Estimated Expiration: ⤷  Start Trial

Patent: 22014414
Patent: COMPUESTOS DE PIRIMIDINODIONA CONTRA ESTADOS CARDIACOS. (PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS.)
Estimated Expiration: ⤷  Start Trial

Morocco

Patent: 789
Patent: Composés de pyrimidine-dione contre les affections cardiaques
Estimated Expiration: ⤷  Start Trial

Netherlands

Patent: 1253
Estimated Expiration: ⤷  Start Trial

New Zealand

Patent: 5456
Patent: Pyrimidinedione compounds against cardiac conditions
Estimated Expiration: ⤷  Start Trial

Norway

Patent: 23043
Estimated Expiration: ⤷  Start Trial

Peru

Patent: 160208
Patent: COMPUESTOS DE PIRIMIDINODIONA CONTRA ESTADOS CARDIACOS
Estimated Expiration: ⤷  Start Trial

Philippines

Patent: 015502794
Patent: PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS
Estimated Expiration: ⤷  Start Trial

Poland

Patent: 10910
Estimated Expiration: ⤷  Start Trial

Portugal

Patent: 10910
Estimated Expiration: ⤷  Start Trial

Serbia

Patent: 906
Patent: PIRIMIDINDIONSKA JEDINJENJA PROTIV SRČANIH STANJA (PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS)
Estimated Expiration: ⤷  Start Trial

Singapore

Patent: 201803459T
Patent: PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS
Estimated Expiration: ⤷  Start Trial

Patent: 201510163T
Patent: PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS
Estimated Expiration: ⤷  Start Trial

Slovenia

Patent: 10910
Estimated Expiration: ⤷  Start Trial

South Africa

Patent: 1508959
Patent: PYRIMIDINEDIONE COMPOUNDS AGAINTS CARDIAC CONDITIONS
Estimated Expiration: ⤷  Start Trial

South Korea

Patent: 2304121
Estimated Expiration: ⤷  Start Trial

Patent: 2359158
Estimated Expiration: ⤷  Start Trial

Patent: 160026997
Patent: 심장 상태에 대한 피리미딘디온 화합물 (PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS)
Estimated Expiration: ⤷  Start Trial

Patent: 210118470
Patent: 심장 상태에 대한 피리미딘디온 화합물 (PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS)
Estimated Expiration: ⤷  Start Trial

Patent: 220020410
Patent: 심장 상태에 대한 피리미딘디온 화합물 (PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS)
Estimated Expiration: ⤷  Start Trial

Patent: 230144117
Patent: 심장 상태에 대한 피리미딘디온 화합물 (PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS)
Estimated Expiration: ⤷  Start Trial

Spain

Patent: 73250
Estimated Expiration: ⤷  Start Trial

Tunisia

Patent: 15000553
Patent: PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS
Estimated Expiration: ⤷  Start Trial

Ukraine

Patent: 7929
Patent: СПОЛУКИ ПІРИМІДИНДІОНУ, СПРЯМОВАНІ ПРОТИ СТАНІВ СЕРЦЕВО-СУДИННОЇ СИСТЕМИ (PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS)
Estimated Expiration: ⤷  Start Trial

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering CAMZYOS around the world.

Country Patent Number Title Estimated Expiration
Australia 2014281408 ⤷  Start Trial
Australia 2018264088 ⤷  Start Trial
Australia 2020204271 ⤷  Start Trial
Australia 2022202298 ⤷  Start Trial
Australia 2024202464 ⤷  Start Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for CAMZYOS

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
3010910 PA2023535,C3010910 Lithuania ⤷  Start Trial PRODUCT NAME: MAVAKAMTENAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA; REGISTRATION NO/DATE: EU/1/23/1716 20230626
3010910 C03010910/01 Switzerland ⤷  Start Trial PRODUCT NAME: MAVACAMTENUM; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 68477 25.04.2023
3010910 PA2023535 Lithuania ⤷  Start Trial PRODUCT NAME: MAVAKAMTENAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA; REGISTRATION NO/DATE: EU/1/23/1716 20230626
3010910 2390030-1 Sweden ⤷  Start Trial PRODUCT NAME: MAVACAMTEN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/23/1716 20230627
3010910 202340028 Slovenia ⤷  Start Trial PRODUCT NAME: MAVACAMTEN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; NATIONAL AUTHORISATION NUMBER: EU/1/23/1716; DATE OF NATIONAL AUTHORISATION: 20230626; AUTHORITY FOR NATIONAL AUTHORISATION: EU
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.